Ranitidine Tablets USP, 150 mg, 500-count bottles, Rx only, Manufactured by: Shasun Pharmaceutica...
FDA Drug Recall #D-1229-2014 — Class II — March 18, 2014
Recall Summary
| Recall Number | D-1229-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | March 18, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Glenmark Generics Inc., USA |
| Location | Mahwah, NJ |
| Product Type | Drugs |
| Quantity | 2904 bottles |
Product Description
Ranitidine Tablets USP, 150 mg, 500-count bottles, Rx only, Manufactured by: Shasun Pharmaceuticals Limited, Unit-II R.S. No 32 33 & 34, Shasun Road, Periyakalapet, Puducherry, - 605 014, India; Manufactured for: Glenmark Generics Inc, USA, Mahwah, NJ 07430, UPC 3 68462 24805 8, NDC 68462-248-05.
Reason for Recall
Presence of Foreign Tablets/Capsules: Recall is due to a pharmacist complaint of a "foreign material", identified as Metoprolol Tartrate Tablet USP 50 mg, found co-mingled in a bottle of Ranitidine Tablets USP 150 mg.
Distribution Pattern
Nationwide
Lot / Code Information
Lot 12AN118A, Exp 10/14
Other Recalls from Glenmark Generics Inc., USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-329-2013 | Class III | Glenmark Gabapentin Tablets, a) 600mg, 500- cou... | Apr 5, 2013 |
| D-330-2013 | Class III | Glenmark Pravastatin Sodium Tablets ,40 mg, 90-... | Apr 5, 2013 |
| D-331-2013 | Class III | Glenmark Topiramate Tablets, 200 mg, 60-count ... | Apr 5, 2013 |
| D-182-2013 | Class III | Montelukast Sodium Tablets, 10 mg (base), packa... | Feb 13, 2013 |
| D-1701-2012 | Class II | NAPROXEN TABLETS USP, 500 mg, 100-count Tablets... | Jul 6, 2012 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.